4.7 Article

Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 157, Issue -, Pages 1376-1394

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2018.08.071

Keywords

Nrf2 activators; Oxadiazole core; Acute liver injury; Structure-activity relationship; Antioxidant function

Funding

  1. National Natural Science Foundation of China [81602948, 81773581, 81773639]
  2. Natural Science Foundation of Jiangsu Province of China [BK20160746]
  3. National Major Science and Technology Project of China (Innovation and Development of New Drugs) [2015ZX09101032, 2017ZX09302003, 2018ZX09711002-003-006]
  4. Priority Academic Program Development of Jiangsu Higher Education Institutions
  5. College Students Innovation Project for the R&D of Novel Drugs [J1310032]
  6. China Postdoctoral Science Foundation [2017M620232]
  7. Program for Outstanding Scientific and Technological Innovation Team of Jiangsu Higher Education [YY20180315004]
  8. Fundamental Research Funds for the Central Universities [2016ZPT005]

Ask authors/readers for more resources

The antioxidant function induced by Nrf2 protects the liver from damage. We found a novel Nrf2 activator named compound 25 via structural modification of compound 1 we previously reported. In vitro, compound 25 induced Nrf2 transport into the nucleus and protected hepatocyte L02 cells from APAP-induced cytotoxicity via activating the Nrf2-ARE signaling pathway. In vivo, 25 exhibited therapeutic effects in a mouse model of acute liver injury induced by acetaminophen (APAP) by up-regulating Nrf2-dependent antioxidases and down-regulating liver injury markers in serum. Together, these results indicated that 25 is a potent Nrf2/ARE activator both in vitro and in vivo. The drug-like properties of compound 25 further revealed its potential for development as a therapeutic drug against acute liver injury. (C) 2018 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available